Related Experiment Video
Updated: Jul 7, 2026
09:34
Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells
Published on: February 9, 2019
Solid lipid nanoparticles for pulmonary delivery of insulin
1Key Laboratory of Drug Targeting, Ministry of Education, Sichuan University, No. 17, Section 3, Southern Renmin Road, Chengdu 610041, PR China.
International Journal of Pharmaceutics
|February 19, 2008
Summary
Novel solid lipid nanoparticles (SLNs) offer a promising non-invasive pulmonary delivery for insulin. These SLNs demonstrated stability, enhanced bioavailability, and prolonged hypoglycemic effects in preclinical studies.
Area of Science:
- Pharmaceutical Sciences
- Nanotechnology
- Drug Delivery
Background:
- The pulmonary route is increasingly explored for non-invasive systemic drug delivery.
- Solid lipid nanoparticles (SLNs) are investigated as carriers for therapeutic agents.
- Pulmonary delivery of insulin aims to overcome limitations of traditional methods.
Purpose of the Study:
- To develop and characterize nebulizer-compatible solid lipid nanoparticles (SLNs) for pulmonary insulin delivery.
- To investigate the impact of sodium cholate (SC) and soybean phosphatidylcholine (SPC) on nanoparticle properties.
- To evaluate the in vitro and in vivo performance of insulin-loaded SLNs (Ins-SLNs) for pulmonary administration.
Main Methods:
- Development of SLNs using the reverse micelle-double emulsion method.
- Optimization of SC and SPC concentrations to improve deposition properties.
- Assessment of entrapment delivery (ED), respirable fraction (RF), and nebulization efficiency (NE).
- In vivo studies involving pulmonary administration of Ins-SLNs to assess glucose-lowering effects and bioavailability.
- Fluorescent labeling of insulin to track nanoparticle distribution in the lungs.
Main Results:
- Optimized SLNs achieved high entrapment delivery (96.53%), respirable fraction (82.11%), and nebulization efficiency (63.28%).
- Ins-SLNs exhibited stability during nebulization and effectively reduced fasting plasma glucose levels by 39.41%.
- Pulmonary administration of Ins-SLNs resulted in increased insulin levels (approx. 170 microIU/ml) and a relative bioavailability of 22.33% compared to subcutaneous injection.
- Fluorescent imaging confirmed homogeneous distribution of Ins-SLNs within the lung alveoli.
Conclusions:
- Nebulizer-compatible SLNs are effective carriers for pulmonary insulin delivery.
- SLNs improve the stability and prolong the hypoglycemic effect of insulin.
- This approach enhances insulin's in vitro and in vivo performance, leading to improved bioavailability.
